Ongoing ADT Use Up to 36 Months Not Linked With Cognitive Decline

Share this content:
Ongoing use of androgen-deprivation therapy for up to 36 months is not associated with cognitive decline among men with prostate cancer.
Ongoing use of androgen-deprivation therapy for up to 36 months is not associated with cognitive decline among men with prostate cancer.

Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer, according to a study published in Cancer.1

Researchers evaluated 3 groups of men who were at least 50 years of age and were matched for age and education. Seventy-seven patients had non-metastatic prostate cancer and initiated continuous ADT, 82 patients had prostate cancer and were not receiving ADT, and 82 were healthy controls.

Over the study period of 26 months, the researchers administered 14 neuropsychological tests that examined 8 cognitive domains on 5 separate occasions.

Through mixed effects models that were adjusted for age and education, the researchers found that ADT use was not associated with significant changes over time in any cognitive test, when compared with healthy controls.

The percentage of patients who declined by at least 1.5 standard deviations in at least 2 tests, or at least 2 standard deviations in at least 1 test, was similar across the observed groups.

RELATED: Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer

There was no significant worsening of cognitive function among patients treated with ADT, compared to controls, upon a global summary of cognitive change.

Reference

  1. Alibhai SMH, Timilshina N, Duff-Canning S, et al. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer. 2016 Aug. doi: 10.1002/cncr.30320 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters